X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OMERS has acquired royalties for Ultomiris (ravulizumab-cwvz), a humanized monoclonal antibody complement inhibitor for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, and Monjuvi (tafasitamab-cxix), used in combination with lenalidomide.
Lead Product(s): Ravulizumab
Therapeutic Area: Rare Diseases and Disorders Product Name: Ultomiris
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: OMERS Life Sciences
Deal Size: $215.0 million Upfront Cash: Undisclosed
Deal Type: Divestment November 07, 2023
Details:
APN-346958 targets a novel RNA-binding protein which is tumor-reactive in at least 50% of samples for six tumor types evaluated, including colorectal, thyroid, head and neck, urothelial, melanoma and brain cancer.
Lead Product(s): APN-346958
Therapeutic Area: Oncology Product Name: APN-346958
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Atreca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
Under the terms of the new agreement, Xencor will receive exclusive worldwide rights to research, develop and commercialize antibody products directed to up to three targets discovered under the collaboration.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Caris Life Sciences
Deal Size: $187.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 05, 2023
Details:
XmAb13676 (plamotamab), is an investigational tumor-targeted XmAb® bispecific antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3).
Lead Product(s): Plamotamab
Therapeutic Area: Oncology Product Name: XmAb13676
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
XmAb®564 is a wholly owned, monovalent IL-2-Fc fusion protein, engineered to selectively activate and expand Tregs for the potential treatment of patients with autoimmune diseases.
Lead Product(s): XmAb564
Therapeutic Area: Dermatology Product Name: XmAb564
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Plamotamab (XmAb13676), is generally well tolerated and demonstrates encouraging clinical activity at our recommended intravenous Phase 2 dose, 50 mg flat dosing every two weeks after step-up dosing.
Lead Product(s): Plamotamab,Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: XmAb13676
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Vudalimab is an XmAb bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation.
Lead Product(s): Vudalimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
XmAb104 is engineered to selectively engage T cells that express both PD-1 and ICOS, important regulators of T cell activity, and we have observed biomarker activity consistent with engagement of both receptors.
Lead Product(s): XmAb23104,Ipilimumab
Therapeutic Area: Oncology Product Name: XmAb104
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
XmAb306 is a potency-reduced IL15/IL15Rα-Fc fusion protein that incorporates Xtend™ extended half-life technology, engineered to be long acting and more drug-like in order to overcome inherent limitations facing cytokine therapeutics.
Lead Product(s): XmAb306
Therapeutic Area: Oncology Product Name: XmAb306
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Preclinical data from two XmAb® cytokine drug programs, a decoy-resistant and potency-reduced IL18-Fc fusion protein, and a LAG-3 targeted IL15/IL15α-Fc fusion protein, which is biased toward binding and activating checkpoint-upregulated lymphocytes will be presented.
Lead Product(s): XmAb306
Therapeutic Area: Oncology Product Name: XmAb306
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
